Nov 6 (Reuters) - Bristol Myers Squibb has acquired Orum’s experimental therapy to treat patients with a type of blood cancer for a total value of up to $180 million, Orum said on Monday. (Reporting by Khushi Mandowara in Bengaluru; Editing by Dhanya Ann Thoppil)
Market Closed -
Other stock markets
|
After market 20:00:00 | |||
44.11 USD | -0.99% | 44.59 | +1.09% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.03% | 90.31B | |
+32.36% | 709B | |
+30.77% | 595B | |
-1.60% | 367B | |
+20.07% | 334B | |
+6.04% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.27% | 171B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol Myers Squibb buys Orum's blood cancer therapy for up to $180 mln